QA-Bio

Executive Summary

QA-Bio is a specialized provider of analytical tools and reagents for glycan analysis, serving the biopharmaceutical development and manufacturing sector. Since its founding in 2002, the company has focused on optimizing chemistries and manufacturing processes to deliver high-performance, convenient kits that are used in FDA and EMA approved procedures worldwide. Its product portfolio supports critical quality control testing for glycoproteins and biologics, enabling drug developers to ensure consistency and safety. With the growing complexity of biologics and biosimilars, QA-Bio's solutions are increasingly vital for regulatory compliance and batch release. The company's established presence in the market and strong reputation for reliability position it as a key enabler in the biologics supply chain.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation glycan analysis platform75% success
• Q4 2026Partnership with a top-20 biopharma for QC workflow standardization60% success
• Q1 2027Expansion into the European biosimilars market with new distribution agreements80% success